BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV) was downgraded by stock analysts at ValuEngine from a “hold” rating to a “sell” rating in a research note issued on Tuesday.

Shares of BiondVax Pharmaceuticals (NASDAQ BVXV) traded down 0.7699% during mid-day trading on Tuesday, hitting $7.1148. 10,121 shares of the stock were exchanged. The stock’s 50 day moving average is $7.16 and its 200-day moving average is $7.16. The stock’s market cap is $31.94 million. BiondVax Pharmaceuticals has a 12 month low of $3.04 and a 12 month high of $8.50.

ILLEGAL ACTIVITY WARNING: “ValuEngine Downgrades BiondVax Pharmaceuticals Ltd. (BVXV) to Sell” was reported by Watch List News and is owned by of Watch List News. If you are accessing this report on another publication, it was copied illegally and republished in violation of U.S. & international copyright and trademark law. The original version of this report can be read at https://www.watchlistnews.com/valuengine-downgrades-biondvax-pharmaceuticals-ltd-bvxv-to-sell/1606256.html.

BiondVax Pharmaceuticals Company Profile

BiondVax Pharmaceuticals Ltd is an Israel-based biopharmaceutical company. The Company holds a worldwide exclusive license granted by Yeda Research and Development Ltd., the commercial arm of the Weizmann Institute, Israel, for developing, manufacturing and commercializing the flu vaccine. BiondVax Pharmaceuticals Ltd develops a biopharmaceutical universal flu vaccine, designed to provide multi-season and multi-strain protection against some human influenza virus strains, including both seasonal and pandemic flu strains.

Receive News & Ratings for BiondVax Pharmaceuticals Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BiondVax Pharmaceuticals Ltd. and related companies with Analyst Ratings Network's FREE daily email newsletter.